A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PTG-200 in Normal Healthy Male Volunteers

Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PTG-200 in Normal Healthy Male Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs PTG 200 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 10 Oct 2017 Status changed from planning to not yet recruiting.
    • 20 Sep 2017 According to a Protagonist Therapeutics media release, this trial is expected to begin before end of 2017.
    • 04 May 2017 According to a Protagonist Therapeutics media release, this trial is expected to begin in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top